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CL IN ICAL  TR IALS  INVOLVING 
VASCULAR GENE TRANSFER 
VEGF OVEREXPRESSION: ANGIOGENESIS  
AND RESTENOSIS 
The prognosis for patients with chronic critical eg ischemia, i.e., 
rest pain and/or established lesions that jeopardize the integrity of 
the lower limbs, is often poor. Psychologic testing of such patients" 
has typically disclosed quality-of-life indices similar to those of 
patients with cancer in critical or even terminal phases of their 
illness. It has been estimated that 150,000 patients require lower- 
limb amputations for ischemic disease in the United States per year. 
Their prognosis after amputation is even worse: the perioperative 
mortality rate for below-knee amputation i most series is 5% to 
10%, and for above knee amputation 15% to 20%. Even when they 
survive, nearly 40% of patients will have died within 2 years of their 
first major amputation; a major amputation is required in 30% of 
cases; and full mobility is achieved in only 50% of below-knee and 
25% of above-knee amputees. 
These grim statistics are compounded by the lack of efficacious 
drug therapy. As concluded in the Consensus Document of the 
European Working Group on Critical Leg Ischemia, " . . .  there 
presently isinadequate evidence from published studies to support 
the routine use of primary pharmacological treatment in patients 
with critical eg ischemia . . . .  " Evidence for the utility of medical 
therapy in the treatment ofclandication is no better. Consequently, 
the need for alternative treatment strategies in such patients is 
compelling. 
The therapeutic mplications of angiogenic growth factors 
were identified by the pioneering work of Folkman and colleagues 
more than two decades ago. More recent investigations have 
established the feasibility of using recombinant formulations of 
such angiogenic growth factors to expedite and/or augment 
collateral artery development in animal models of myocardial nd 
hind-limb ischemia. This novel strategy for the treatment of 
vascular insufficiency has been termed "therapeutic angiogenesis." 
Among the various growth factors that have been shown to 
promote angiogenesis, vascular endothelial growth factor (VEGF), 
also known as vascular permeability factor (VPF), and vasculotropin 
(VAS) are endothelial-cell specific mitogens. Because ndothelial 
cells represent the critical cell type responsible for new vessel 
formation, and because smooth muscle cells---one of the critical cell 
types responsible for the development of certain vascular lesions-- 
would not be directly activated, cell-type specificity has been 
considered to represent an important advantage of VEGF for 
therapeutic angiogenesis. 
VEGF is further distinguished from other angiogenic yto- 
kines by the fact that the first exon of the VEGF gene includes a 
secretory signal sequence that permits the protein to be naturally 
secreted from intact cells. Previous tudies from our laboratory had 
shown that arterial gene transfer of cDNA encoding for a secreted 
protein could yield meaningful biologic outcomes despite a low 
transfection efficiency. We therefore performed preclinical animal 
studies to establish the feasibility of site-specific gene transfer of 
phVEGF16s, encoding the 165-amino acid isoform of VEGF, 
applied to the hydrogel polymer coating of an angioplasty balloon, 
and delivered percutaneously to the iliac artery of rabbits in which 
the femoral artery had been excised to cause unilateral hind-limb 
ischemia. Analysis of the transfected internal iliac arteries using 
reverse transcription-polymerase chain reaction (RT-PCR) con- 
firmed reproducible gene expression atthe mRNA level for up to 21 
days after gene transfer. Augmented evelopment of collateral 
vessels was documented by serial angiograms invivo and increased 
capillary density at necropsy. Consequent amelioration of the 
hemodynamic deficit in the ischemic limb was documented by 
improvement in the calf blood pressure ratio (ischemic/normal 
limb), as well as increased resting and maximum vasodilator- 
induced blood flow in the VEGF-transfected animals versus con- 
trois transfected with a reporter gene. 
Clinical investigation of arterial gene therapy for therapeutic 
angiogenesis was performed in seven patients with critical limb 
ischemia, using a dose-escalating, open label, unblinded protocol. 
The primary objective of this phase 1 study was to document the 
safety ofphVEGFi65 arterial gene therapy for therapeutic anglo- 
genesis. The secondary objective was to determine the bioactivity of 
arterial gene therapy using phVEGF16 s to relieve rest pain and/or 
heal ischemic ulcers of the lower extremities in patients with 
peripheral rtery disease. 
Percutaneous arterial gene transfer was performed in four 
patients with ischemic ulcers and lower extremity rest pain, and 
three patients with rest pain alone. A hydrogel-coated balloon 
angioplasty catheter was used to perform percutaneous arterial 
gene transfer of phVEGF16s, a eucaryotic expression plasmid 
encoding for the 165-amino acid isoform of vascular endothelial 
growth factor (VEGF), to a lower extremity arterial site. Patients 
received 100 Bg (n = 1), 500 gg (n = 1), or 1000 ~tg (n = 5) of 
naked plasrnid DNA without adjunctive vectors. 
The three patients who had with rest pain alone, each of whom 
received 1000 ~tg of phV~,GF16s~ experienced resolution of rest 
pain, and remain free of rest pain 3 months after gene transfer. In 
all three patients, magnetic resonance angiography (MRA) docu- 
mented improved perfusion of the inftapopliteal circulation; a
corresponding improvement in total limb blood flow was docu- 
mented using an intravascular Doppler wire; and acceleration of 
contrast media transit ime from the site of injection (common 
femoral artery) to the ankle was observed. 
Among the four patients who had ischemic ulcers, ulcer size 
stabilized transiently in one patient who received 1000 gg, but 
continued to progress in the other three patients treated with 100 
gg, 500 ~tg, and 1000 gg, respectively. 
Follow-up intravascular ultrasound examination disclosed no 
evidence of new atherosclerotic plaque at the site ofgene transfer in 
any patient. Likewise, no patient experienced new-onset peripheral 
edema, ophthalmologic complications, or other systemic toxicity 
attributable to phVEGF16 5arterial gene transfer. 
Arterial gene transfer of naked DNA encoding for vascular 
endothelial growth factor can be performed safely using percuta- 
neous catheter delivery. In three patients, areduction in rest pain 
associated with increased blood flow demonstrated by MRA, 
intravascular Doppler measurement, and contrast angiography 
suggests that this strategy has potential bioactivity as well. Larger 
doses of naked plasmid DNA and/or adjunctive vectors may be 
useful to augment the bioactivity of gene therapy for therapeutic 
angiogenesis. 
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